Continuous Naproxen Sodium Tableting Without Granulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional tableting processes for naproxen sodium require a granulation step due to its low flow properties, leading to non-uniformity and segregation, and often include a glidant like colloidal silicon dioxide, which increases costs and complexity.
Innovation Solution
A continuous manufacturing process using a loss-in-weight feeder and a tablet press with three rollers eliminates the need for granulation and glidants, allowing direct compression of naproxen sodium tablets without segregation, thereby improving efficiency and reducing costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If granulation process is used to improve flowability of naproxen sodium powder, then flow properties are improved, but process complexity and manufacturing cost increase
Solution Approach 1:
The patent removes the granulation step from the conventional tableting process. By using a specialized loss-in-weight feeder with enhanced agitation and aeration mechanisms, the process directly feeds naproxen sodium powder without requiring granulation, thereby simplifying the manufacturing process while maintaining flow properties
Solution Approach 2:
The patent changes the operating parameters of the loss-in-weight feeder, specifically optimizing agitation speed, aeration rate, and feed rate to enable direct feeding of low-flow naproxen sodium powder. These parameter adjustments allow the powder to flow adequately without granulation
2Ease of operation
If granulation process is used to transform low-flow powder to granules, then flowability is improved, but manufacturing time and efficiency are reduced
Solution Approach 1:
The granulation step is completely removed from the process. The loss-in-weight feeder is modified with enhanced agitation and aeration to directly handle and feed naproxen sodium powder, eliminating the time-consuming granulation and drying steps while maintaining adequate flowability for direct compression
Solution Approach 2:
The patent implements a continuous feeding process using the loss-in-weight feeder that maintains constant material flow to the tablet press. This continuous action eliminates the batch processing nature of granulation, thereby improving manufacturing efficiency and throughput
3Ease of operation
If glidant is added to enhance flow of naproxen sodium, then flow properties are improved, but product cost and complexity increase
Solution Approach 1:
The patent eliminates the need for glidant additives by modifying the loss-in-weight feeder with enhanced agitation and aeration mechanisms. These mechanical modifications enable the naproxen sodium powder to achieve adequate flow properties through physical means rather than chemical additives, thereby reducing product cost and simplifying the formulation
Solution Approach 2:
The loss-in-weight feeder with enhanced agitation and aeration enables the naproxen sodium powder to self-flow adequately without requiring external glidant assistance. The system uses its own enhanced mechanical actions to overcome the poor flow properties of the powder
4Device complexity
If conventional two-roller tablet press is used for compression, then manufacturing simplicity is maintained, but blend densification is insufficient leading to poor tablet quality
Solution Approach 1:
The patent combines the functions of blend densification and tablet compression into a single integrated three-roller tablet press. The first two rollers perform preliminary compression to densify the blend, and the third roller completes the compression to form the final tablet, achieving both densification and tablet formation in one device
Solution Approach 2:
The first two rollers of the three-roller tablet press perform preliminary compression to densify the blend before the final compression step. This preliminary action ensures adequate densification of the low-flow naproxen sodium powder, preventing poor tablet quality while maintaining device simplicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enables cost-effective production of naproxen sodium tablets with improved uniformity and reduced potential for errors, eliminating the need for glidants and granulation steps, thus enhancing manufacturing efficiency and reducing waste.
Implementation Method 1
loss-in-weight feeder particularly designed for low-flow materials
Implementation Method 2
tablet press with three rollers facilitating direct compression
Implementation Method 3
the third roller acts as a roller compactor in situ following pre and main compression of the blend
Data Source
AI summary
Provided are oral tablets comprising naproxen sodium, mannitol, a superdisintegrant, and a lubricant. The oral tablets described herein to not comprise a glidant (e.g. colloidal silicon dioxide). These oral tablets may be manufactured using the process of mixing naproxen sodium, mannitol, a superdisintegrant, and magnesium stearate in a continuous in-line mixer to form a tableting mixture; transferring the tableting mixture to a tablet press including three or more compression rollers; and pressing the tableting mixture into naproxen sodium tablets.